Moody’s Investors Service assigned a rating of Baa1 to the new senior unsecured note issuance of Amgen Inc. (NASDAQ;AMGN). There are no changes to Amgen’s existing ratings or negative rating outlook. Amgen, Inc. (NASDAQ:AMGN) net profit margin is 24.90% and weekly performance is 1.27%. On last trading day company shares ended up $113.49. Analysts mean target price for the company is $132.78. Amgen, Inc. (NASDAQ:AMGN) distance from 50-day simple moving average (SMA50) is -2.81%.
AstraZeneca PLC (NYSE:AZN) shareholders question the Board of Directors decision to flatly reject Pfizer’s (NYSE: PFE) final bid of $92.53, or £55 per share. AstraZeneca plc (ADR) (NYSE:AZN) shares advanced 2.04% in last trading session and ended the day on $73.67. AZN gross Margin is 79.80% and its return on assets is 3.70%.AstraZeneca plc (ADR) (NYSE:AZN) quarterly performance is 10.58%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) fell after the company reported a net loss per share of 12 cents in the first quarter of 2014, missing the Zacks Consensus Estimate of earnings of 10 cents. Arena had incurred a narrower loss of 9 cents in the year-ago quarter. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved down -0.47% in last trading session and was closed at $6.30, while trading in range of $6.24 – $6.49. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is 7.69%.
Effective May 15, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ;ARIA) granted an exemption to BlackRock, Inc., together with its subsidiaries, affiliates and associates under the Company’s Section 382 Rights Agreement, dated as of October 31, 2013, between the Company and Computershare Trust Company, N.A., as rights agent following the determination by a designated committee of the Board of Directors of the Company that BlackRock and the various investment funds and accounts for which BlackRock acts, or may in the future act, as manager and/or investment advisor, are collectively an “Exempt Person” pursuant to Section 29 of the Rights Agreement. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended the last trading day at $6.35. Company weekly volatility is calculated as 4.51% and price to cash ratio as 5.00.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -4.51%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. On last trading day company shares ended up $37.15.
Leave a Reply